Commercialisation Plans

A brilliant piece of medical research does not win an MRFF grant on science alone. Commercialisation planning can account for 20 per cent or more of the total assessment score in many Medical Research Future Fund rounds. Get that section wrong and the whole bid struggles, no matter how ground-breaking the data look in vitro.

Grant Savvy writes the commercial story that turns lab success into a fundable, scalable product.

Why Commercialisation Plans Matter

• They prove your discovery can leave the bench and reach real patients.
• They reassure assessors that public money will trigger private follow-on investment and sustainable revenue.
• They map a realistic path through patents, regulation, manufacturing, reimbursement and market uptake.
• They give reviewers a clear return-on-investment narrative they can defend to Treasury and the Minister.

Miss any of those points and the panel will mark your application as “high risk”.

Common Gaps We See

Most MRFF bids come from brilliant scientists. That is the strength—and the weak spot. Typical gaps include:

• Market size is quoted, but no segment analysis or payer behaviour.
• Patent filed, but freedom-to-operate and licence strategy unaddressed.
• Manufacturing is costed only at lab scale, ignoring GMP or scale-up.
• Regulatory path is listed as “TGA approval” with no timelines or evidence package.
• Reimbursement plan is a single sentence: “Will seek MBS listing.”
• No demonstration of investor interest or matched funding beyond the grant.

Any one of these can shave crucial points off the commercialisation score.

How Grant Savvy Bridges Science And Market

Before launching Grant Savvy I spent four years consulting to med-tech start-ups, writing their early business plans and preparing their first MRFF submissions. I understand the language of assay sensitivity and primary endpoints—but I also know venture capital, cost of goods, and how long the Therapeutic Goods Administration really takes.

Here is what we add to your team:

Commercial Reality Check

We stress-test your market narrative, competitor landscape and payer logic so the plan reads like a board-ready business case, not a conference abstract.

Financial Story That Adds Up

We build milestone-based budgets, GMP cost estimates, cost-of-goods projections and headline IRR scenarios. Assessors see exactly where the money goes and how value is created.

Clear IP And Freedom-To-Operate Path

We summarise patent status, exclusivity windows and licensing options in plain English, tied to your technology readiness level and clinical milestones.

Regulatory And Reimbursement Road-map

Step-by-step timelines for TGA, FDA or CE Mark, with evidence packages and health-economic endpoints aligned to eventual payer expectations.

Investor Alignment

We highlight matched funding, co-investment commitments and exit options—key signals panels look for under “Overall Value and Risk”.

Our Process

1. Kick-off call – fifteen minutes to confirm round, deadlines and data you already have.
2. Data room build – you drop raw science, existing IP docs, any market research. We create a gap list so nothing is guessed.
3. Draft plan – we write the commercial story, map the milestones, cost the phases, outline risk mitigations. Live Google Doc for comments.
4. Refine and integrate – we align budgets with the scientific work plan, cross-check timelines, add letters of support from industry partners or investors.
5. Final polish and upload – plain-language edit, guideline compliance, PDF formatting and portal submission.

Standard turnaround is three to four weeks. If your data are ready and deadlines tight, we can compress to ten working days.

Experience That Counts

• Supported successful MRFF bids across Early-Stage Translation, Clinical Trials and Commercialisation streams—totaling multi-million-dollar awards.
• Worked with biologics, smart implants, digital therapeutics and point-of-care diagnostics.
• Regularly collaborate with university tech-transfer offices, contract research organisations and specialist patent attorneys, so your plan reflects the whole commercial ecosystem.

Ready To Strengthen Your MRFF Bid?

A fifteen-minute call is usually enough to spot whether the commercial section will pass or fail. If it needs work, we will outline exactly what to fix and how we can help. If it is already strong, we will tell you that too.